Corona Remedies LtdNSE:CORONA
Current view Q4 2026
Steady branded-medicine maker growing twice as fast as the market, and it beat its own targets. New brands, weight-loss drug launch and fertility push add fresh growth; management delivers.
Latest exchange filings last 5 · 5 after Q4 2026
- 10 Sep ’26Corona Remedies clarifies share volume movement is market-driven, with no undisclosed price-sensitive information. ↗
- 10 Sep ’26Exchange has sought clarification from Corona Remedies Ltd on September 10, 2026, with reference to Movement in Volume.
- 20 Aug ’26Company officials will attend Phillip Capital PCG investor conference in Ahmedabad on August 26, 2026. ↗
- 10 Aug ’26Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026 ↗
- 10 Aug ’26Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Aug ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +20.1% | +3.2% | +16.6% | +19.5% |
| Operating profit | ▲ +14.8% | −25.3% | +28.3% | +22.5% |
| EPS | ▲ +43.6% | +9.8% | +29.6% | −26.4% |
| PAT | ▲ +40.6% | +9.8% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +20.1%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average61/100
Cheap, and growing fast. Profit per share grew 30% a year, while the price-tag on its earnings actually got smaller. That gap — real growth nobody has paid up for — is exactly what this score looks for.
₹2,053 → ₹4,107 needs the P/E at 62× — it is 68× today, and has ranged 48× to 65× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 93× — never traded above 65× in 5 years.
At ₹1,692 the price-tag on its earnings reaches the 56× it is being projected toward — the point where being cheap against that yardstick is used up.
Unpaid, but the growth quality is thin. Verify before acting.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a mid-cap at ₹13,086 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 29.6% — the weakest of
EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 44%. Price move is a proxy (distance from the 40-week EMA) until ret1y is stored.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Corona Remedies | ₹2,179 | 62.8× | ₹13,326 Cr | 33.3% | +30.1% | +21.9% |
| Sun Pharma.Inds. | ₹1,853 | 35.1× | ₹4.45 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,379 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,855 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,152 | 23.6× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,375 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | broadly flat | operating margin 21% → 22% over 21 months |
|---|---|---|
| Did the profit turn into cash? | more than all of it — reserves released cash too | 95% last year, 101% over three · free cash flow ₹56 cr, positive in 3 of 4 years |
| Is the growth borrowed? | lightly borrowed | ₹165 cr — 0.22× its own equity (was 0.14×) |
| Is it being collected? | collection is steady | 38 days to collect, up 2 in a year · cash cycle 7 days |
| Who has been buying? | promoter stake unchanged on record | promoters 69.0% · FIIs 3.6% · DIIs 12.9% |
| What does it earn on its capital? | earns a high return on the capital it employs | ROCE 33.3% · ROE 29.5% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
- Company has been maintaining a healthy dividend payout of 29.3%
Against it
- Stock is trading at 17.8 times its book value
- Company might be capitalizing the interest cost
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.